Nebulized Ketamine for the Treatment of Major Depressive Disorder

Clinical trial NCT06752759 · RECRUITING

Trial details

NCT number: NCT06752759
Sponsor: Theresa Jacob, PhD, MPH
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Severe Depression Moderate Depression Ketamine Midazolam Peripheral Nervous System Agents Central Nervous System Agents Neurotransmitter Agents Physiologic Effects of Drugs Sensory System Agents Analgesics, Non-Narcotic Anti-Inflammatory Agents, Non-Steroidal Depressive Symptom

Start date: 2024-10-16
Primary completion: 2027-09-30
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.